{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:48:27Z","timestamp":1784576907284,"version":"3.55.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007380","name":"Fondation de l'Avenir pour la Recherche M\u00e9dicale Appliqu\u00e9e","doi-asserted-by":"publisher","award":["AP-RM-23-008"],"award-info":[{"award-number":["AP-RM-23-008"]}],"id":[{"id":"10.13039\/100007380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013414","name":"Regional Council of Pays de la Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031376","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","award":["ANR-23-CE17-0037"],"award-info":[{"award-number":["ANR-23-CE17-0037"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cytogfr.2025.10.007","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:38:31Z","timestamp":1760827111000},"page":"137-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Targeting the colony-stimulating factor 1 axis for the treatment of Tenosynovial Giant Cell Tumors"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-5550","authenticated-orcid":false,"given":"Paul","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Vialle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Chevalerias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Crenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Waast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Astrid","family":"Boutet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.007_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/14728222.2022.2067040","article-title":"Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches","volume":"26","author":"Spierenburg","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/TUB-220005","article-title":"Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor","volume":"44","author":"Tap","year":"2022","journal-title":"Tumor Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib3","first-page":"93","article-title":"Tenosynovial giant cell tumor","volume":"62","author":"Kager","year":"2022","journal-title":"Folia Med. Cracov."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib5","doi-asserted-by":"crossref","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2020","journal-title":"Pathologica"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib6","first-page":"1","article-title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry","author":"Stern","year":"2025","journal-title":"Future Oncol. Lond. Engl."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/gcc.22807","article-title":"Detection of Csf1 rearrangements deleting the 3\u2019 utr in tenosynovial giant cell tumors","volume":"59","author":"Ho","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides","volume":"31","author":"Cupp","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"22","key":"10.1016\/j.cytogfr.2025.10.007_bib10","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-Driven tenosynovial giant cell tumors","volume":"28","author":"van IJzendoorn","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib11","doi-asserted-by":"crossref","first-page":"a021857","DOI":"10.1101\/cshperspect.a021857","article-title":"CSF-1 receptor signaling in myeloid cells","volume":"6","author":"Stanley","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102904","article-title":"Therapeutic advances in tenosynovial giant cell tumor: targeting the CSF1\/CSF1R axis","volume":"134","author":"Assi","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.007_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tcb.2004.09.016","article-title":"CSF-1 regulation of the wandering macrophage: complexity in action","volume":"14","author":"Pixley","year":"2004","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.007_bib15","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/j.1460-2075.1987.tb02561.x","article-title":"Human CSF-1: gene structure and alternative splicing of mRNA precursors","volume":"6","author":"Ladner","year":"1987","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.10.007_bib16","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.intimp.2008.04.016","article-title":"Macrophage colony stimulating factor: not just for macrophages anymore! a gateway into complex biologies","volume":"8","author":"Douglass","year":"2008","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib17","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1074\/mcp.M112.025288","article-title":"Nucleolin mediates MicroRNA-directed CSF-1 mRNA deadenylation but increases translation of CSF-1 mRNA*","volume":"12","author":"Woo","year":"2013","journal-title":"Mol. Cell Proteom."},{"issue":"31","key":"10.1016\/j.cytogfr.2025.10.007_bib18","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1016\/S0021-9258(17)32085-9","article-title":"Structural analysis of proteoglycan macrophage colony-stimulating factor","volume":"269","author":"Kimura","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2003-08-2739","article-title":"Incomplete restoration of colony-stimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op\/Csf1op mice by transgenic expression of cell surface CSF-1","volume":"103","author":"Dai","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood-2005-05-1822","article-title":"Developmental and functional significance of the CSF-1 proteoglycan chondroitin sulfate chain","volume":"107","author":"Nandi","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.007_bib21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","article-title":"The M-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101514","article-title":"Clinical evaluation of colony-stimulating factor 1 receptor inhibitors","volume":"54","author":"Ordentlich","year":"2021","journal-title":"Semin Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3RU0316-144R","article-title":"Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage","volume":"100","author":"Ushach","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrrheum.2014.198","article-title":"Alternative pathways of osteoclastogenesis in inflammatory arthritis","volume":"11","author":"Adamopoulos","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.10.007_bib26","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/emboj\/18.13.3616","article-title":"The cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation","volume":"18","author":"Lee","year":"1999","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/gcc.2870040312","article-title":"Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: confirmation of trisomy 7 in uncultured cells","volume":"4","author":"Fletcher","year":"1992","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/1097-0142(19910101)67:1<121::AID-CNCR2820670122>3.0.CO;2-P","article-title":"Cytogenetic evidence of clonality in a case of pigmented villonodular synovitis","volume":"67","author":"Ray","year":"1991","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.007_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0046-8177(92)90340-9","article-title":"Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis","volume":"23","author":"Abdul-Karim","year":"1992","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/1098-2264(2000)9999:9999<::AID-GCC1096>3.0.CO;2-C","article-title":"Trisomy 7 accumulates with age in solid tumors and non-neoplastic synovia","volume":"30","author":"Broberg","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00428-002-0640-y","article-title":"Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors","volume":"441","author":"Nilsson","year":"2002","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-022-01266-9","article-title":"Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue","volume":"17","author":"Sugita","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.05.010","article-title":"RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors","volume":"115","author":"Thangaiah","year":"2021","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.007_bib34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/jor.25216","article-title":"Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF-1, driving tenosynovial giant cell tumor","volume":"40","author":"Chandler","year":"2022","journal-title":"J. Orthop. Res Publ. Orthop. Res Soc."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib35","article-title":"Single-Cell analysis clarifies pathological heterogeneity in tenosynovial giant cell tumor and identifies biomarkers for predicting disease recurrence","author":"Xie","year":"2025","journal-title":"Adv. Sci. Weinh. Baden. Wurtt. Ger."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/gcc.20501","article-title":"Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors","volume":"47","author":"M\u00f6ller","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3892\/ijo.2014.2326","article-title":"Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors","volume":"44","author":"Panagopoulos","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.10.007_bib38","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/0008-5472.CAN-04-3954","article-title":"Glyceraldehyde-3-Phosphate dehydrogenase binds to the AU-Rich 3\u2032 untranslated region of Colony-Stimulating Factor\u20131 (CSF-1) messenger RNA in human ovarian cancer cells: possible role in CSF-1 posttranscriptional regulation and tumor phenotype","volume":"65","author":"Bonaf\u00e9","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-11-58","article-title":"Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152","volume":"11","author":"Woo","year":"2012","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","article-title":"Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT","volume":"28","author":"Tap","year":"2022","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.10.007_bib41","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/ijc.32421","article-title":"Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations","volume":"145","author":"Tsuda","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.007_bib42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/gcc.23116","article-title":"A novel colony-stimulating factor 1 (CSF1) translocation involving human endogenous retroviral element in a tenosynovial giant cell tumor","volume":"62","author":"Lipplaa","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/cancers14030839","article-title":"Role of CBL mutations in cancer and Non-Malignant phenotype","volume":"14","author":"Leardini","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.10.007_bib44","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrm1762","article-title":"The cbl interactome and its functions","volume":"6","author":"Schmidt","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib45","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.E23-09-0345","article-title":"The ubiquitin ligases cbl and Cbl-b regulate macrophage growth by controlling CSF-1R import into macropinosomes","volume":"35","author":"Huang","year":"2024","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1012527","article-title":"Expanding the molecular spectrum of tenosynovial giant cell tumors","volume":"12","author":"Gauduchon","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cancers12010100","article-title":"Molecular profiling of atypical tenosynovial giant cell tumors reveals novel Non-CSF1 fusions","volume":"12","author":"Vougiouklakis","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s13577-022-00823-0","article-title":"Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis","author":"Thongchot","year":"2022","journal-title":"Hum. Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib49","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s13018-023-04279-2","article-title":"Identification of potential diagnostic biomarkers for tenosynovial giant cell tumour by integrating microarray and single-cell RNA sequencing data","volume":"18","author":"Chen","year":"2023","journal-title":"J. Orthop. Surg."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib50","doi-asserted-by":"crossref","DOI":"10.1101\/2021.09.29.462128","article-title":"Single-cell RNA-seq analysis reveals aberrant CSF1 expression in disease-causing synovial fibroblasts of pigmented villonodular synovitis [Internet]","author":"Tang","year":"2021","journal-title":"Mol. Biol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1445427","article-title":"Case report: tenosynovial giant cell tumor","volume":"14","author":"F\u00e4hnrich","year":"2024","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ajcp\/69.1.6","article-title":"Giant cell tumor of tendon sheath and pigmented villonodular synovitis: an ultrastructural study","volume":"69","author":"Alguacil-Garcia","year":"1978","journal-title":"Am. J. Clin. Pathol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.007_bib53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0046-8177(95)90226-0","article-title":"Giant cell tumor of tendon sheath and pigmented villonodular synovitis: immunophenotype suggests a synovial cell origin","volume":"26","author":"O\u2019connell","year":"1995","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.007_bib54","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/PAS.0b013e3181a6d86f","article-title":"Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications","volume":"33","author":"Boland","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1440-1827.1995.tb03435.x","article-title":"Giant cell tumors of tendon sheath: a single and multiple immunostaining analysis","volume":"45","author":"Tashiro","year":"1995","journal-title":"Pathol. Int."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib56","first-page":"876","article-title":"Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors","volume":"12","author":"Zheng","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.007_bib57","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.007_bib58","first-page":"1383","article-title":"Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts","volume":"150","author":"Darling","year":"1997","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib59","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/hupa.2003.52","article-title":"Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis","volume":"34","author":"Yoshida","year":"2003","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.2937","article-title":"Osteoclast formation and function in pigmented villonodular synovitis","volume":"225","author":"Taylor","year":"2011","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.007_bib61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/bjc.1991.125","article-title":"Bone resorption by macrophage polykaryons of giant cell tumour of tendon sheath","volume":"63","author":"Athanasou","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib62","article-title":"Gene expression profiles analyzed using integrating RNA sequencing, and microarray reveals increased inflammatory response, proliferation, and osteoclastogenesis in pigmented villonodular synovitis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2017.02.021","article-title":"Giant cell tumour of bone in the denosumab era","volume":"77","author":"van der Heijden","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib64","first-page":"469","article-title":"Treatment of tenosynovial giant cell tumor of the cervical spine with postoperative Anti-RANKL antibody (Denosumab) administration","volume":"78","author":"Hirata","year":"2024","journal-title":"Acta Med. Okayama"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib65","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/path.1891","article-title":"Synovial fluid macrophages are capable of osteoclast formation and resorption","volume":"208","author":"Adamopoulos","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2024.08.034","article-title":"Formation and biological activities of foreign body giant cells in response to biomaterials","volume":"188","author":"Cai","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106234","article-title":"Idiopathic pulmonary hemosiderosis: a state of the art review","volume":"176","author":"Saha","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib68","first-page":"563","article-title":"Chapter 35 - overview of cerebrospinal fluid cytology","volume":"145","author":"Rahimi","year":"2018"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib69","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/modpathol.3800715","article-title":"Iron overload syndromes and the liver","volume":"20","author":"Batts","year":"2007","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib70","first-page":"92","article-title":"Iron overload due to mutations in ferroportin","volume":"91","author":"De Domenico","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.007_bib71","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3324\/haematol.2010.023879","article-title":"Polarization dictates iron handling by inflammatory and alternatively activated macrophages","volume":"95","author":"Corna","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib72","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/eji.200939889","article-title":"Differential regulation of iron homeostasis during human macrophage polarized activation","volume":"40","author":"Recalcati","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196921","article-title":"Cell iron status influences macrophage polarization","volume":"13","author":"Agoro","year":"2018","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13244-023-01367-z","article-title":"MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment","volume":"14","author":"Spierenburg","year":"2023","journal-title":"Insights Imaging"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.10.007_bib75","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.it.2019.10.002","article-title":"Foam cells: one size doesn\u2019t fit all","volume":"40","author":"Guerrini","year":"2019","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib76","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2018.01.012","article-title":"Lipid droplets as immune modulators in myeloid cells","volume":"39","author":"den Brok","year":"2018","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/83348","article-title":"PPAR-\u03b1 and PPAR-\u03b3 activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway","volume":"7","author":"Chinetti","year":"2001","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib78","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","article-title":"TOPP study group, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume":"16","author":"Bernthal","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.007_bib80","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib","volume":"105","author":"Dewar","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.007_bib81","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib82","first-page":"S28","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib84","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg. Oncol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib85","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib86","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib87","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided blockade of CSF1R kinase in tenosynovial Giant-Cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib88","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.70068","article-title":"Necroptotic suppression of lung cancer cell proliferation and migration: a comprehensive in vitro and in silico study to determine new molecular targets for pexidartinib","volume":"43","author":"Hac\u0131osmano\u011flu-Aldo\u011fan","year":"2025","journal-title":"Cell Biochem. Funct."},{"issue":"10197","key":"10.1016\/j.cytogfr.2025.10.007_bib89","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet Lond. Engl."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.10.007_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae345","article-title":"Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study","volume":"30","author":"Wagner","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib91","article-title":"A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib","author":"Desai","year":"2024","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib92","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of tenosynovial giant cell tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-0103","article-title":"CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: a phase 1 study of vimseltinib","author":"Gelderblom","year":"2024","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"10445","key":"10.1016\/j.cytogfr.2025.10.007_bib95","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet Lond. Engl."},{"issue":"16","key":"10.1016\/j.cytogfr.2025.10.007_bib96","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2023.41.16_suppl.11559","article-title":"Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): phase 1b update","volume":"41","author":"Yao","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib97","first-page":"1","article-title":"MANEUVER: a phase III study of pimicotinib to assess efficacy and safety in tenosynovial giant cell tumor patients","author":"Niu","year":"2024","journal-title":"Future Oncol. Lond. Engl."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.10.007_bib98","doi-asserted-by":"crossref","first-page":"C160","DOI":"10.1158\/1535-7163.TARG-23-C160","article-title":"Abstract C160: HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment","volume":"22","author":"Hu","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1189\/jlb.1209822","article-title":"Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells","volume":"88","author":"Wei","year":"2010","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.10.007_bib100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.56875\/2589-0646.1032","article-title":"Updates on the treatment of tenosynovial giant cell tumor","volume":"16","author":"Chan","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.10.007_bib101","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib102","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"15","key":"10.1016\/j.cytogfr.2025.10.007_bib103","doi-asserted-by":"crossref","first-page":"11078","DOI":"10.1200\/JCO.2017.35.15_suppl.11078","article-title":"A phase I\/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)","volume":"35","author":"Sankhala","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib104","article-title":"Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumor","volume":"229","author":"van de Sande","year":"2025","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"16","key":"10.1016\/j.cytogfr.2025.10.007_bib105","doi-asserted-by":"crossref","first-page":"TPS11585","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS11585","article-title":"A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor","volume":"41","author":"Gelderblom","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.10.007_bib106","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1124\/jpet.118.254128","article-title":"Colony-Stimulating Factor-1 antibody lacnotuzumab in a phase 1 healthy volunteer study and mechanistic investigation of safety outcomes","volume":"369","author":"Pognan","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib107","article-title":"MCS110, an anti-CSF-1 antibody, for the treatment of pigmented villonodular synovitis (PVNS)","author":"Cheng","year":"2015","journal-title":"ISOLS\/MSTS 2015 Annu. Meet."},{"issue":"598","key":"10.1016\/j.cytogfr.2025.10.007_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd4550","article-title":"Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition","volume":"13","author":"Bissinger","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib109","article-title":"Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist sotuletinib","volume":"3","author":"Pognan","year":"2022","journal-title":"Curr. Res. Toxicol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib110","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/jid.2011.67","article-title":"The genetic determination of skin pigmentation: kitlg and the kitlg\/c-Kit pathway as key players in the onset of human familial pigmentary diseases","volume":"131","author":"Picardo","year":"2011","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib111","article-title":"Genomic profiling in GIST: implications in clinical outcome and future challenges","volume":"48","author":"Calderillo-Ru\u00edz","year":"2024","journal-title":"Neoplasia New Y N."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib112","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/his.13744","article-title":"Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?","volume":"74","author":"Mastboom","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.cytogfr.2025.10.007_bib113","doi-asserted-by":"crossref","DOI":"10.1111\/odi.70003","article-title":"Single-Cell RNA sequencing study on two synovial derived tumors in the temporomandibular joint","author":"Han","year":"2025","journal-title":"Oral. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-025-03590-z","article-title":"IFN\u03b3 production during cell interactions distinguishes localized from diffuse pigmented villonodular synovitis and rheumatoid arthritis","volume":"27","author":"Noack","year":"2025","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.820046","article-title":"Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features","volume":"13","author":"Robert","year":"2022","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.10.007_bib116","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.autrev.2010.07.001","article-title":"Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis","volume":"9","author":"Fiocco","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.10.007_bib117","first-page":"1675","article-title":"Treatment modalities for Refractory-Recurrent tenosynovial giant cell tumor (TGCT): an update","volume":"60","author":"Dania","year":"2024","journal-title":"Med Kaunas. Lith."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.10.007_bib118","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1136\/annrheumdis-2013-204589","article-title":"Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour","volume":"73","author":"Nissen","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.900010","article-title":"Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: the REALIZE study","volume":"12","author":"Takeuchi","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.cytogfr.2025.10.007_bib120","article-title":"Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK\/STAT signaling","author":"Lu","year":"2025","journal-title":"Sci. China Life Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.10.007_bib121","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41584-018-0123-4","article-title":"Intra-articular treatment options for knee osteoarthritis","volume":"15","author":"Jones","year":"2019","journal-title":"Nat. Rev. Rheuma"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib122","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1021\/acsbiomaterials.5c00597","article-title":"Hydrogel-Based strategies for managing rheumatoid arthritis: from sustained drug release to Cell-Based therapies","volume":"11","author":"Back","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.10.007_bib123","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.10.007_bib124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CORR.0000000000002335","article-title":"Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: results from ENLIVEN","volume":"481","author":"Healey","year":"2023","journal-title":"Clin. Orthop."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:21:53Z","timestamp":1781234513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":124,"alternative-id":["S1359610125001418"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.007","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the colony-stimulating factor 1 axis for the treatment of Tenosynovial Giant Cell Tumors","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}